Opioid receptors in GtoPdb v.2023.1 Opioid receptors in GtoPdb v.2023.1
暂无分享,去创建一个
E. J. Simon | H. Ueda | M. Bruchas | B. Kieffer | Y. Wong | A. Zimmer | O. Civelli | L. Liu-Chen | C. Chavkin | G. Calo’ | S. Husbands | J. Traynor | P. Portoghese | C. Evans | J. Meunier | N. Zaveri | L. Toll | I. Kitchen | M. Connor | B. Cox | E. Kelly | G. Henderson | M. Christie | D. Malfacini | A. Borsodi | V. Höllt | D. Massot | S. Schulz | -. Mary | Lakshmi | S. Toni | A. Devi | J. Kreek | Shippenberg | -. Mary
[1] B. Roth,et al. Structures of the entire human opioid receptor family , 2023, Cell.
[2] Samuel T. Slocum,et al. Structure-based design of bitopic ligands for the µ-opioid receptor , 2022, Nature.
[3] Xi Cheng,et al. Molecular recognition of morphine and fentanyl by the human μ-opioid receptor , 2022, Cell.
[4] Graeme Henderson,et al. Biased Agonism: Lessons from Studies of Opioid Receptor Agonists. , 2022, Annual review of pharmacology and toxicology.
[5] G. Skiniotis,et al. Structure‐Based Evolution of G Protein‐Biased μ‐Opioid Receptor Agonists , 2022, bioRxiv.
[6] Joseph M. Paggi,et al. Insights into distinct signaling profiles of the µOR activated by diverse agonists , 2022, Nature Chemical Biology.
[7] M. J. Robertson,et al. Structure Determination of Inactive-State GPCRs with a Universal Nanobody , 2021, bioRxiv.
[8] V. Sreenivasan,et al. Intrinsic Efficacy of Opioid Ligands and Its Importance for Apparent Bias, Operational Analysis, and Therapeutic Window , 2020, Molecular Pharmacology.
[9] Elyssa B. Margolis,et al. Biased signaling by endogenous opioid peptides , 2020, Proceedings of the National Academy of Sciences.
[10] N. Nic Daéid,et al. Activation of μ‐opioid receptors by MT‐45 (1‐cyclohexyl‐4‐(1,2‐diphenylethyl)piperazine) and its fluorinated derivatives , 2020, British Journal of Pharmacology.
[11] Reid H. J. Olsen,et al. Nanobody-enabled monitoring of kappa opioid receptor states , 2020, Nature Communications.
[12] C. Ruzza,et al. Detailed In Vitro Pharmacological Characterization of the Clinically Viable Nociceptin/Orphanin FQ Peptide Receptor Antagonist BTRX-246040 , 2020, The Journal of Pharmacology and Experimental Therapeutics.
[13] Peter Buneman,et al. Why data citation isn't working, and what to do about it , 2020, Database J. Biol. Databases Curation.
[14] J. Streicher,et al. A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy with Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models. , 2020, The journal of pain : official journal of the American Pain Society.
[15] Andrew M. Piggott,et al. A tetrapeptide class of biased analgesics from an Australian fungus targets the µ-opioid receptor , 2019, Proceedings of the National Academy of Sciences.
[16] V. Tékus,et al. A Novel G Protein–Biased Agonist at the δ Opioid Receptor with Analgesic Efficacy in Models of Chronic Pain , 2019, The Journal of Pharmacology and Experimental Therapeutics.
[17] Xinzhong Dong,et al. Discovery of Benzamidine- and 1-Aminoisoquinoline-Based Human MAS-Related G-Protein-Coupled Receptor X1 (MRGPRX1) Agonists. , 2019, Journal of medicinal chemistry.
[18] Steven J Brown,et al. Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140). , 2019, Journal of medicinal chemistry.
[19] D. Selley,et al. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands. , 2019, Journal of medicinal chemistry.
[20] S. Salvadori,et al. In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP‐505 , 2018, British journal of pharmacology.
[21] S. Novello,et al. Anti‐Parkinsonian and anti‐dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists , 2018, British journal of pharmacology.
[22] Kathryn E. Livingston,et al. Pharmacologic Evidence for a Putative Conserved Allosteric Site on Opioid Receptors , 2018, Molecular Pharmacology.
[23] Ryan T. Strachan,et al. Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor , 2018, Cell.
[24] W. Rubas,et al. NKTR-181: A Novel Mu-Opioid Analgesic with Inherently Low Abuse Potential , 2017, The Journal of Pharmacology and Experimental Therapeutics.
[25] Henry Lin,et al. Structure-based discovery of opioid analgesics with reduced side effects , 2016, Nature.
[26] M. von Zastrow,et al. Molecular Pharmacology of δ-Opioid Receptors , 2016, Pharmacological Reviews.
[27] R. Stevens,et al. The Importance of Ligand-Receptor Conformational Pairs in Stabilization: Spotlight on the N/OFQ G Protein-Coupled Receptor. , 2015, Structure.
[28] M. Bruchas,et al. Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor , 2015, Molecular Pharmacology.
[29] P. Pinton,et al. Pharmacological Profile of Nociceptin/Orphanin FQ Receptors Interacting with G-Proteins and β-Arrestins 2 , 2015, PloS one.
[30] Stephen M. Husbands,et al. Structural insights into μ-opioid receptor activation , 2015, Nature.
[31] Kathryn E. Livingston,et al. Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor. , 2015, Journal of medicinal chemistry.
[32] N. Zaveri,et al. Discovery of the First Small-Molecule Opioid Pan Antagonist with Nanomolar Affinity at Mu, Delta, Kappa, and Nociceptin Opioid Receptors , 2015, ACS chemical neuroscience.
[33] Anton Barty,et al. Structural basis for bifunctional peptide recognition at human δ-Opioid receptor , 2015, Nature Structural &Molecular Biology.
[34] L. Devi,et al. Challenges for opioid receptor nomenclature: IUPHAR Review 9 , 2015, British journal of pharmacology.
[35] S. Salvadori,et al. In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives , 2014, British journal of pharmacology.
[36] E. Bullmore,et al. The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours , 2014, Psychopharmacology.
[37] K. Schiene,et al. Cebranopadol: A Novel Potent Analgesic Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[38] D. McKinzie,et al. Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffold. , 2014, Journal of medicinal chemistry.
[39] P. Veinante,et al. A mu–delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks , 2014, Brain Structure and Function.
[40] D. McKinzie,et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders , 2014, Neuropharmacology.
[41] Bryan L. Roth,et al. Molecular control of δ-opioid receptor signalling , 2014, Nature.
[42] A. M. Phillips,et al. Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors* , 2013, The Journal of Biological Chemistry.
[43] G. Pasternak,et al. Mu Opioids and Their Receptors: Evolution of a Concept , 2013, Pharmacological Reviews.
[44] Bryan L. Roth,et al. Selective κ Opioid Antagonists nor-BNI, GNTI and JDTic Have Low Affinities for Non-Opioid Receptors and Transporters , 2013, PloS one.
[45] M. Banks,et al. Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor , 2013, Proceedings of the National Academy of Sciences.
[46] B. Bradley,et al. Amygdala-Dependent Fear Is Regulated by Oprl1 in Mice and Humans with PTSD , 2013, Science Translational Medicine.
[47] M. Morari,et al. Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK‐21273 in comparison with SB‐612111 , 2013, British journal of pharmacology.
[48] B. Kieffer,et al. Impaired Hippocampus-Dependent and Facilitated Striatum-Dependent Behaviors in Mice Lacking the Delta Opioid Receptor , 2013, Neuropsychopharmacology.
[49] M. Spetea,et al. Discovery and biological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist , 2012, BMC Pharmacology and Toxicology.
[50] P. Wade,et al. Identification of a dual δ OR antagonist/μ OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d). , 2012, Bioorganic & medicinal chemistry letters.
[51] Aashish Manglik,et al. Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.
[52] J. Neumeyer,et al. Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors. , 2012, Journal of medicinal chemistry.
[53] Bryan L. Roth,et al. Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.
[54] L. Pardo,et al. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.
[55] D. Lambert,et al. Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505). , 2012, British journal of anaesthesia.
[56] B. Kieffer,et al. Localization and regulation of fluorescently labeled delta opioid receptor, expressed in enteric neurons of mice. , 2011, Gastroenterology.
[57] G. Pasternak,et al. Generation of novel radiolabeled opiates through site-selective iodination. , 2011, Bioorganic & medicinal chemistry letters.
[58] Timothy J Kropp,et al. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. , 2011, Regulatory toxicology and pharmacology : RTP.
[59] R. Maldonado,et al. Deletion of the δ Opioid Receptor Gene Impairs Place Conditioning But Preserves Morphine Reinforcement , 2011, Biological Psychiatry.
[60] S. Husbands,et al. The First Universal Opioid Ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): Characterization of the In Vitro Profile and In Vivo Behavioral Effects in Mouse Models of Acute Pain and Cocaine-Induced Reward , 2011, Journal of Pharmacology and Experimental Therapeutics.
[61] Walter A. Korfmacher,et al. Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models. , 2010, European journal of pharmacology.
[62] N. Zaveri,et al. Comparison of the Antinociceptive and Antirewarding Profiles of Novel Bifunctional Nociceptin Receptor/μ-Opioid Receptor Ligands: Implications for Therapeutic Applications , 2009, Journal of Pharmacology and Experimental Therapeutics.
[63] Adam J Kuszak,et al. Purification and functional reconstitution of monomeric mu-opioid receptors: allosteric modulation of agonist binding by Gi2. , 2009, The Journal of biological chemistry.
[64] T. Graczyk,et al. Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747). , 2009, Journal of medicinal chemistry.
[65] S. Salvadori,et al. Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. , 2009, European journal of pharmacology.
[66] J. Bidlack,et al. Syntheses of novel high affinity ligands for opioid receptors. , 2009, Bioorganic & medicinal chemistry letters.
[67] L. Terenius. Stereospecific interaction between narcotic analgesics and a synaptic plasm a membrane fraction of rat cerebral cortex. , 2009, Acta pharmacologica et toxicologica.
[68] J. Lötsch,et al. A Common Human μ-Opioid Receptor Genetic Variant Diminishes the Receptor Signaling Efficacy in Brain Regions Processing the Sensory Information of Pain* , 2009, Journal of Biological Chemistry.
[69] E. Kostenis,et al. Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5 , 2009, Naunyn-Schmiedeberg's Archives of Pharmacology.
[70] Hiroshi. Nakamura,et al. Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug. , 2009, Journal of medicinal chemistry.
[71] T. Graczyk,et al. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859). , 2008, Journal of medicinal chemistry.
[72] J. Neumeyer,et al. Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors. , 2008, Bioorganic & medicinal chemistry letters.
[73] D. Tulshian,et al. The Anxiolytic-Like Effects of the Novel, Orally Active Nociceptin Opioid Receptor Agonist 8-[bis(2-Methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510) , 2008, Journal of Pharmacology and Experimental Therapeutics.
[74] David G. Lambert,et al. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential , 2008, Nature Reviews Drug Discovery.
[75] J. Cassel,et al. Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor. , 2008, Bioorganic & medicinal chemistry letters.
[76] S. Salvadori,et al. Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist , 2008, Peptides.
[77] アレキサンダー,ロベルタ,ヴェッザ,et al. Synthetic peptide amides , 2007 .
[78] K. Schiene,et al. (–)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties , 2007, Journal of Pharmacology and Experimental Therapeutics.
[79] S. Salvadori,et al. In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor , 2007, Peptides.
[80] R. Ciccocioppo,et al. Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In Vivo Studies , 2007, Journal of Pharmacology and Experimental Therapeutics.
[81] D. Lambert,et al. Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In Vitro Studies , 2007, Journal of Pharmacology and Experimental Therapeutics.
[82] A. Basbaum,et al. Knockin mice expressing fluorescent delta-opioid receptors uncover G protein-coupled receptor dynamics in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[83] S. Salvadori,et al. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor. , 2006, CNS drug reviews.
[84] C. Tränkle,et al. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.
[85] S. Salvadori,et al. Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist. , 2006, Bioorganic & medicinal chemistry.
[86] Y. Iwasawa,et al. Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity. , 2006, Journal of medicinal chemistry.
[87] F. Heppner,et al. Detection of kappa and delta opioid receptors in skin--outside the nervous system. , 2005, Biochemical and biophysical research communications.
[88] E. Novellino,et al. Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as mu-opioid receptor imaging agents. , 2005, Journal of medicinal chemistry.
[89] S. Salvadori,et al. Blockade of Nociceptin/Orphanin FQ Transmission Attenuates Symptoms and Neurodegeneration Associated with Parkinson's Disease , 2005, The Journal of Neuroscience.
[90] C. Woolf. Faculty Opinions recommendation of Interaction with vesicle luminal protachykinin regulates surface expression of delta-opioid receptors and opioid analgesia. , 2005 .
[91] G. Calo’,et al. Functional Selectivity of Nociceptin/Orphanin FQ Peptide Receptor Partial Agonists on Cardiovascular and Renal Function , 2005, Journal of Pharmacology and Experimental Therapeutics.
[92] T. F. Murray,et al. [Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist. , 2005, Journal of medicinal chemistry.
[93] Cécile Béguin,et al. Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2). , 2005, Bioorganic & medicinal chemistry letters.
[94] J. Bidlack,et al. Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone. , 2005, Bioorganic & medicinal chemistry letters.
[95] M. Kreek,et al. Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments , 2005, Pharmacological Reviews.
[96] T. Yeh,et al. Heterodimerization of opioid receptor‐like 1 and µ‐opioid receptors impairs the potency of µ receptor agonist , 2005, Journal of neurochemistry.
[97] S. Salvadori,et al. [(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a Highly Potent and Selective Agonist of the Nociceptin/Orphanin FQ Receptor , 2005, Journal of Pharmacology and Experimental Therapeutics.
[98] S. Salvadori,et al. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands. , 2005, Journal of medicinal chemistry.
[99] V. Höllt,et al. Genetic disposition to addictive disorders--current knowledge and future perspectives. , 2005, Current opinion in pharmacology.
[100] J. Lötsch,et al. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? , 2005, Trends in molecular medicine.
[101] S. Schulz,et al. Receptor Endocytosis Counteracts the Development of Opioid Tolerance , 2005, Molecular Pharmacology.
[102] C. Abbadie,et al. Immunohistochemical study of the expression of EXON11-containing μ opioid receptor variants in mouse brain , 2004, Neuroscience.
[103] M. Narita,et al. Increased level of neuronal phosphoinositide 3-kinase γ by the activation of μ-opioid receptor in the mouse periaqueductal gray matter: further evidence for the implication in morphine-induced antinociception , 2004, Neuroscience.
[104] J. Ott,et al. Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. , 2004, Pharmacogenetics.
[105] D. Kyle,et al. Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor. , 2004, Bioorganic & medicinal chemistry letters.
[106] R. Schulz,et al. Opioid control of MAP kinase cascade. , 2004, European journal of pharmacology.
[107] M. Zenk,et al. Endogenous formation of morphine in human cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[108] N. Mercuri,et al. Blockade of Nociceptin/orphanin Fq Receptor Signaling in Rat Substantia Nigra Pars Reticulata Stimulates Nigrostriatal Dopaminergic Transmission and Motor Behavior ,lys 15 ]n/ofq(1–13)-nh 2 ) (a Selective Nop Receptor Peptide Antagonist) Stimulated It. N/ofq Microinjected in the Sub- Stantia Nigra P , 2022 .
[109] L. Fan,et al. Changes in acetylcholinesterase activity and muscarinic receptor bindings in mu-opioid receptor knockout mice. , 2004, Brain research. Molecular brain research.
[110] B. Kieffer,et al. Deficit in Attachment Behavior in Mice Lacking the µ-Opioid Receptor Gene , 2004, Science.
[111] A. Beaudet,et al. Mu-opioid receptor knockout prevents changes in delta-opioid receptor trafficking induced by chronic inflammatory pain , 2004, Pain.
[112] K. Befort,et al. The delta agonists DPDPE and deltorphin II recruit predominantly mu receptors to produce thermal analgesia: a parallel study of mu, delta and combinatorial opioid receptor knockout mice , 2004, The European journal of neuroscience.
[113] Bryan L Roth,et al. Salvinorin A, an Active Component of the Hallucinogenic Sage Salvia divinorum Is a Highly Efficacious κ-Opioid Receptor Agonist: Structural and Functional Considerations , 2004, Journal of Pharmacology and Experimental Therapeutics.
[114] J. Miller,et al. Abundant expression of mu and delta opioid receptor mRNA and protein in the cerebellum of the fetal, neonatal, and adult rat. , 2004, Brain research. Developmental brain research.
[115] I. Sora,et al. mu-Opioid receptor knockout mice display reduced cocaine conditioned place preference but enhanced sensitization of cocaine-induced locomotion. , 2004, Brain research. Molecular brain research.
[116] M. Scheideler,et al. Modification of Nociception and Morphine Tolerance by the Selective Opiate Receptor-Like Orphan Receptor Antagonist (–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) , 2004, Journal of Pharmacology and Experimental Therapeutics.
[117] S. Kaasa,et al. Genetic analysis of the murine μ opioid receptor: increased complexity of Oprm gene splicing , 2004, Journal of Molecular Medicine.
[118] G. Pasternak,et al. Functional analysis of MOR‐1 splice variants of the mouse mu opioid receptor gene Oprm , 2004, Synapse.
[119] L. Ma,et al. Chronic morphine treatment and withdrawal induce up-regulation of c-jun n-terminal kinase 3 gene expression in rat brain , 2003, Neuroscience.
[120] S. Schulz,et al. Heterodimerization of Substance P and μ-Opioid Receptors Regulates Receptor Trafficking and Resensitization* , 2003, Journal of Biological Chemistry.
[121] K. Payza. Binding and Activity of Opioid Ligands at the Cloned Human Delta, Mu, and Kappa Receptors , 2003 .
[122] M. Narita,et al. Reduced expression of a novel µ‐opioid receptor (MOR) subtype MOR‐1B in CXBK mice: Implications of MOR‐1B in the expression of MOR‐mediated responses , 2003, The European journal of neuroscience.
[123] A. Beaudet,et al. Phylogenetic changes in the expression of delta opioid receptors in spinal cord and dorsal root ganglia , 2003, The Journal of comparative neurology.
[124] W Zieglgänsberger,et al. [3h]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain , 2003, Neuroscience.
[125] A. Forge,et al. The opioid receptors in inner ear of different stages of postnatal rats , 2003, Hearing Research.
[126] B. Kieffer,et al. Basal and morphine‐evoked dopaminergic neurotransmission in the nucleus accumbens of MOR‐ and DOR‐knockout mice , 2003, The European journal of neuroscience.
[127] Sabita Roy,et al. Morphine Negatively Regulates Interferon-γ Promoter Activity in Activated Murine T Cells through Two Distinct Cyclic AMP-dependent Pathways* , 2003, Journal of Biological Chemistry.
[128] H. Loh,et al. Impaired water maze learning performance in mu-opioid receptor knockout mice. , 2003, Brain research. Molecular brain research.
[129] J. Williams,et al. Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone‐inducible mammalian expression system , 2003, British journal of pharmacology.
[130] S. Allouche,et al. Pharmacological characterization of AR-M1000390 at human delta opioid receptors. , 2003, Life sciences.
[131] A. Forge,et al. The presence of opioid receptors in rat inner ear , 2003, Hearing Research.
[132] N. Zaveri. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. , 2003, Life sciences.
[133] H. Loh,et al. Differential effects of morphine and cocaine on locomotor activity and sensitization in μ-opioid receptor knockout mice , 2003, Neuroscience Letters.
[134] H. Takeshima,et al. Normal sensitivity to acute pain, but increased inflammatory hyperalgesia in mice lacking the nociceptin precursor polypeptide or the nociceptin receptor , 2003, The European journal of neuroscience.
[135] C. Gaveriaux-Ruff,et al. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. , 2003, The Journal of clinical investigation.
[136] H. Ueda,et al. In Vivo Pain-Inhibitory Role of Nociceptin/Orphanin FQ in Spinal Cord , 2003, Journal of Pharmacology and Experimental Therapeutics.
[137] R. Bertorelli,et al. Blockade of nociceptin/orphanin FQ–NOP receptor signalling produces antidepressant‐like effects: pharmacological and genetic evidences from the mouse forced swimming test , 2003, The European journal of neuroscience.
[138] J. Roder,et al. Differential involvement of the Mu and Kappa opioid receptors in spatial learning , 2003, Genes, brain, and behavior.
[139] Juei-Tang Cheng,et al. Rapid induction of insulin resistance in opioid μ-receptor knock-out mice , 2003, Neuroscience Letters.
[140] J. Pintar,et al. Nociceptin/orphanin FQ knockout mice display up-regulation of the opioid receptor-like 1 receptor and alterations in opioid receptor expression in the brain , 2003, Neuroscience.
[141] S. Schulz,et al. ADP-ribosylation Factor-dependent Phospholipase D2 Activation Is Required for Agonist-induced μ-Opioid Receptor Endocytosis* , 2003, The Journal of Biological Chemistry.
[142] R. Maldonado,et al. Acute antinociceptive responses in single and combinatorial opioid receptor knockout mice: distinct mu, delta and kappa tones , 2003, The European journal of neuroscience.
[143] D. Filliol,et al. Enhanced humoral response in kappa-opioid receptor knockout mice , 2003, Journal of Neuroimmunology.
[144] S. Hanessian,et al. The power of visual imagery in drug design. Isopavines as a new class of morphinomimetics and their human opioid receptor binding activity. , 2003, Journal of medicinal chemistry.
[145] D. Lambert,et al. Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5‐hydroxytryptamine and noradrenaline release in the rat neocortex , 2003, British journal of pharmacology.
[146] A. Beaudet,et al. Up-regulation and trafficking of δ opioid receptor in a model of chronic inflammation: implications for pain control , 2003, Pain.
[147] M. Gunzer,et al. Localization of μ-opioid receptor 1A on sensory nerve fibers in human skin , 2002, Regulatory Peptides.
[148] L. Jan,et al. Contribution of GIRK2-mediated postsynaptic signaling to opiate and α2-adrenergic analgesia and analgesic sex differences , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[149] R. Maldonado,et al. Attenuation of Nicotine-Induced Antinociception, Rewarding Effects, and Dependence in μ-Opioid Receptor Knock-Out Mice , 2002, The Journal of Neuroscience.
[150] De-Pei Li,et al. Activation of delta-opioid receptors excites spinally projecting locus coeruleus neurons through inhibition of GABAergic inputs. , 2002, Journal of neurophysiology.
[151] H. Akil,et al. Expression of orphanin FQ and the opioid receptor-like (ORL1) receptor in the developing human and rat brain , 2002, Journal of Chemical Neuroanatomy.
[152] J. Pintar,et al. Autoradiography of opioid and ORL1 ligands in opioid receptor triple knockout mice , 2002, The European journal of neuroscience.
[153] D. Filliol,et al. Quantitative autoradiographic mapping of opioid receptors in the brain of δ-opioid receptor gene knockout mice , 2002, Brain Research.
[154] G. Koob,et al. Lack of reward and locomotor stimulation induced by heroin in mu-opioid receptor-deficient mice. , 2002, European journal of pharmacology.
[155] T. Kenakin,et al. G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.
[156] S. Salvadori,et al. [Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor , 2002, British journal of pharmacology.
[157] S. Salvadori,et al. Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.
[158] C. Gaveriaux-Ruff,et al. Opioid receptor genes inactivated in mice: the highlights , 2002, Neuropeptides.
[159] Y. Wong,et al. Co-Expressions of Different Opioid Receptor Types Differentially Modulate Their Signaling via G16 , 2002, Neurosignals.
[160] H. Schroeder,et al. Rewarding effects of ethanol and cocaine in µ opioid receptor-deficient mice , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.
[161] I. Zagon,et al. The biology of the opioid growth factor receptor (OGFr) , 2002, Brain Research Reviews.
[162] L. Bohn,et al. Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade. , 2001, Journal of neurochemistry.
[163] G. Pasternak,et al. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[164] L. Devi,et al. G-protein-coupled receptor dimerization: modulation of receptor function. , 2001, Pharmacology & therapeutics.
[165] D Horvath,et al. From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands. , 2001, Journal of medicinal chemistry.
[166] G. Pasternak,et al. Differential in vivo internalization of MOR-1 and MOR-1C by morphine , 2001, Neuroreport.
[167] W. Sadee,et al. μ-Opioid Receptor-mediated ERK Activation Involves Calmodulin-dependent Epidermal Growth Factor Receptor Transactivation* , 2001, The Journal of Biological Chemistry.
[168] G. Pasternak,et al. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. , 2001, Pharmacological reviews.
[169] V. Höllt,et al. C-terminal Splice Variants of the Mouse μ-Opioid Receptor Differ in Morphine-induced Internalization and Receptor Resensitization* , 2001, The Journal of Biological Chemistry.
[170] G. Beilman,et al. Morphine directs T cells toward T(H2) differentiation. , 2001, Surgery.
[171] F I Carroll,et al. Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. , 2001, Journal of medicinal chemistry.
[172] T. Eisenstein,et al. Opioids, opioid receptors, and the immune response. , 2001, Drug and alcohol dependence.
[173] D. Filliol,et al. A Single Nucleotide Polymorphic Mutation in the Human μ-Opioid Receptor Severely Impairs Receptor Signaling* , 2001, The Journal of Biological Chemistry.
[174] I. Sora,et al. Ethanol consumption and reward are decreased in µ-opiate receptor knockout mice , 2001, Psychopharmacology.
[175] E. Valjent,et al. Lack of dependence and rewarding effects of deltorphin II in mu‐opioid receptor‐deficient mice , 2001, The European journal of neuroscience.
[176] G. Adam,et al. Synthesis of (1S,3aS)-8- (2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro [4.5]decan-4-one, a Potent and Selective Orphanin FQ (OFQ) Receptor Agonist with Anxiolytic-Like Properties. , 2000 .
[177] A. Basbaum,et al. Postsynaptic Signaling via the μ-Opioid Receptor: Responses of Dorsal Horn Neurons to Exogenous Opioids and Noxious Stimulation , 2000, The Journal of Neuroscience.
[178] Y. Yamada,et al. Highly potent nociceptin analog containing the Arg-Lys triple repeat. , 2000, Biochemical and biophysical research communications.
[179] L. Devi,et al. Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[180] H. Yamada,et al. 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity. , 2000, Journal of medicinal chemistry.
[181] H. Ueda,et al. Enhanced Spinal Nociceptin Receptor Expression Develops Morphine Tolerance and Dependence , 2000, The Journal of Neuroscience.
[182] J. Costentin,et al. Autoradiographic localization of [3H]nociceptin binding sites in the rat brain , 2000, Brain Research.
[183] G. Adam,et al. Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. , 2000, European journal of medicinal chemistry.
[184] B. O'dowd,et al. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. , 2000, The Journal of biological chemistry.
[185] Y. Iwasawa,et al. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. , 2000, European journal of pharmacology.
[186] T. Kroslak,et al. Allelic variation S268P of the human mu-opioid receptor affects both desensitization and G protein coupling. , 2000, Molecular pharmacology.
[187] S. Salvadori,et al. Nociceptin/orphanin FQ receptor ligands , 2000, Peptides.
[188] C. Topham,et al. The nociceptin (ORL1) receptor: molecular cloning and functional architecture , 2000, Peptides.
[189] L. Moulédous,et al. Tissue distribution of the opioid receptor-like (ORL1) receptor , 2000, Peptides.
[190] B. Hawes,et al. Cellular actions of nociceptin: transduction mechanisms , 2000, Peptides.
[191] R. M. Jones,et al. Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. , 2000, Journal of medicinal chemistry.
[192] H. Schroeder,et al. Morphine self-administration in µ-opioid receptor-deficient mice , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.
[193] M. Krug,et al. Lack of expression of long-term potentiation in the dentate gyrus but not in the CA1 region of the hippocampus of μ-opioid receptor-deficient mice , 2000, Neuropharmacology.
[194] G. Adam,et al. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[195] G. Pasternak,et al. Differential distribution in rat brain of mu opioid receptor carboxy terminal splice variants MOR‐1C‐like and MOR‐1‐like immunoreactivity: Evidence for region‐specific processing , 2000, The Journal of comparative neurology.
[196] S. Salvadori,et al. Characterization of [Nphe1]nociceptin(1‐13)NH2, a new selective nociceptin receptor antagonist , 2000, British journal of pharmacology.
[197] J. Menzies,et al. In vitro agonist effects of nociceptin and [Phe(1)psi(CH(2)-NH)Gly(2)]nociceptin(1-13)NH(2) in the mouse and rat colon and the mouse vas deferens. , 1999, European journal of pharmacology.
[198] I. Zagon,et al. Cloning, sequencing, expression and function of a cDNA encoding a receptor for the opioid growth factor, [Met5]enkephalin 1 The nucleotide sequence of the rat OGFr has been deposited in GenBank under accession number AF 156878. 1 , 1999, Brain Research.
[199] Y. Iwasawa,et al. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). , 1999, Journal of medicinal chemistry.
[200] D. Richter,et al. Reverse physiology in Drosophila: identification of a novel allatostatin‐like neuropeptide and its cognate receptor structurally related to the mammalian somatostatin/galanin/opioid receptor family , 1999, The EMBO journal.
[201] H. Masuda,et al. Modification of acetylcholine release by nociceptin in conscious rat striatum , 1999, Brain Research.
[202] H. Akil,et al. Opioid receptor‐like (ORL1) receptor distribution in the rat central nervous system: Comparison of ORL1 receptor mRNA expression with 125I‐[14Tyr]‐orphanin FQ binding , 1999, The Journal of comparative neurology.
[203] D. Kapusta,et al. Cardiovascular and renal responses produced by central orphanin FQ/nociceptin occur independent of renal nerves. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.
[204] H. Ueda,et al. Dose-related opposite modulation by nociceptin/orphanin FQ of substance P nociception in the nociceptors and spinal cord. , 1999, The Journal of pharmacology and experimental therapeutics.
[205] F. Simonin,et al. Ligands for κ-Opioid and ORL1 Receptors Identified from a Conformationally Constrained Peptide Combinatorial Library* , 1999, The Journal of Biological Chemistry.
[206] A. Loizzo,et al. Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats , 1999, Neuroscience Letters.
[207] Joshua F. Nitsche,et al. Retention of Supraspinal Delta-like Analgesia and Loss of Morphine Tolerance in δ Opioid Receptor Knockout Mice , 1999, Neuron.
[208] G. Adam,et al. 8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists. , 1999, Bioorganic & medicinal chemistry letters.
[209] M. Connor,et al. OPIOID RECEPTOR SIGNALLING MECHANISMS , 1999, Clinical and experimental pharmacology & physiology.
[210] Pll Siinksen,et al. Control , 1999, Netherlands Journal of Plant Pathology.
[211] D. Lambert,et al. Comparison of the effects of [Phe1Ψ(CH2‐NH)Gly2]Nociceptin (1–13)NH2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin receptors , 1999, British journal of pharmacology.
[212] J. Pintar,et al. μ‐opioid receptor modulation of calcium channel current in periaqueductal grey neurons from C57B16/J mice and mutant mice lacking MOR‐1 , 1999, British journal of pharmacology.
[213] C. Maggi,et al. Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[214] H. Akil,et al. Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor. , 1999, The Journal of pharmacology and experimental therapeutics.
[215] D. Peckys,et al. Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study , 1999, Neuroscience.
[216] Shengwen Zhang,et al. Endomorphins fully activate a cloned human mu opioid receptor , 1998, FEBS letters.
[217] H. Loh,et al. MU-opioid receptor-knockout mice: role of μ-opioid receptor in morphine mediated immune functions , 1998 .
[218] M. Kathmann,et al. Nociceptin inhibits noradrenaline release in the mouse brain cortex via presynaptic ORL1 receptors , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.
[219] J. Pintar,et al. Expression of opioid receptors and ligands in pregnant mouse uterus and placenta. , 1998, Biology of reproduction.
[220] H. Ueda,et al. Nociceptin/orphanin FQ-induced nociceptive responses through substance P release from peripheral nerve endings in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[221] T. Manabe,et al. Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors , 1998, Nature.
[222] J A Tischfield,et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[223] T. Kaneko,et al. Immunocytochemical localization of μ-opioid receptor in primary afferent neurons containing substance P or calcitonin gene-related peptide. A light and electron microscope study in the rat , 1998, Brain Research.
[224] S. Schulz,et al. Carboxyl-terminal Splicing of the Rat μ Opioid Receptor Modulates Agonist-mediated Internalization and Receptor Resensitization* , 1998, The Journal of Biological Chemistry.
[225] H. Matthes,et al. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[226] B. Ashby,et al. Agonist-induced desensitization and down-regulation of the human kappa opioid receptor expressed in Chinese hamster ovary cells. , 1998, The Journal of pharmacology and experimental therapeutics.
[227] H. Masuda,et al. Modification of dopamine release by nociceptin in conscious rat striatum , 1998, Brain Research.
[228] Yoshihiro Yoshihara,et al. Nocistatin, a peptide that blocks nociceptin action in pain transmission , 1998, Nature.
[229] Sabita Roy,et al. Evidence for opioid receptors on cells involved in host defense and the immune system , 1998, Journal of Neuroimmunology.
[230] A. Cavalli,et al. mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. , 1998, Brain research. Molecular brain research.
[231] J. M. Kennedy,et al. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. , 1998, NIDA research monograph.
[232] B. Roques,et al. Disruption of the κ‐opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ‐agonist U‐50,488H and attenuates morphine withdrawal , 1998, The EMBO journal.
[233] S. Salvadori,et al. A new selective antagonist of the nociceptin receptor , 1998, British journal of pharmacology.
[234] F. Monsma,et al. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[235] P. Szekeres,et al. Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. , 1997, The Journal of pharmacology and experimental therapeutics.
[236] D. Mangoura,et al. μ‐Opioids activate tyrosine kinase focal adhesion kinase and regulate cortical cytoskeleton proteins cortactin and vinculin in chick embryonic neurons , 1997, Journal of neuroscience research.
[237] R. Houghten,et al. Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. , 1997, The Journal of pharmacology and experimental therapeutics.
[238] L. Devi,et al. Dimerization of the delta opioid receptor: implication for a role in receptor internalization. , 1997, The Journal of biological chemistry.
[239] S. Schulz,et al. Immunolocalization of two mu-opioid receptor isoforms (MOR1 and MOR1B) in the rat central nervous system , 1997, Neuroscience.
[240] L. Toll,et al. Relationship between binding affinity and functional activity of nociceptin/orphanin FQ , 1997, Neuropeptides.
[241] V. Pickel,et al. Ultrastructural immunocytochemical localization of μ-opioid receptors in dendritic targets of dopaminergic terminals in the rat caudate–putamen nucleus , 1997, Neuroscience.
[242] H. Akil,et al. Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract , 1997, Neuroscience.
[243] J. Li,et al. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. , 1997, The Journal of pharmacology and experimental therapeutics.
[244] S. Salvadori,et al. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. , 1997, Journal of medicinal chemistry.
[245] H. Jansen,et al. Altered Hematopoiesis, Behavior, and Sexual Function in μ Opioid Receptor–deficient Mice , 1997, The Journal of experimental medicine.
[246] J. Kuno,et al. Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor , 1997, The EMBO journal.
[247] I. Sora,et al. The mu-opioid receptor is necessary for [D-Pen2,D-Pen5]enkephalin-induced analgesia. , 1997, European journal of pharmacology.
[248] Z. Vogel,et al. Opiate-induced Adenylyl Cyclase Superactivation Is Isozyme-specific* , 1997, The Journal of Biological Chemistry.
[249] I. Sora,et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[250] E. V. Van Bockstaele,et al. Mu‐opioid receptor is located on the plasma membrane of dendrites that receive asymmetric synapses from axon terminals containing leucine‐enkephalin in the rat nucleus locus coeruleus , 1996, The Journal of comparative neurology.
[251] P B Bradley,et al. International Union of Pharmacology. XII. Classification of opioid receptors. , 1996, Pharmacological reviews.
[252] D. Lambert,et al. Nociceptin induced inhibition of K+ evoked glutamate release from rat cerebrocortical slices , 1996, British journal of pharmacology.
[253] B. O'dowd,et al. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein. , 1996, Molecular pharmacology.
[254] Brigitte L. Kieffer,et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene , 1996, Nature.
[255] M. Parmentier,et al. Replacement of Gln280 by His in TM6 of the human ORL1 receptor increases affinity but reduces intrinsic activity of opioids , 1996, FEBS letters.
[256] G. Gebhart,et al. Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. , 1996, Gastroenterology.
[257] T. Schwartz,et al. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor. , 1996, Molecular pharmacology.
[258] G. Makhlouf,et al. Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle. , 1996, Molecular pharmacology.
[259] A. Pande,et al. Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain. , 1996, Clinical neuropharmacology.
[260] T. Hales,et al. Voltage-dependent inhibition of Ca2+ channels in GH3 cells by cloned mu- and delta-opioid receptors. , 1996, Molecular pharmacology.
[261] N. Maidment,et al. Intracerebroventricular orphanin FQ/Nociceptin supresses dopamine release in the nucleus accumbens of anaesthetized rats , 1996, Neuroscience.
[262] V. Neugebauer,et al. The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. , 1996, European journal of pharmacology.
[263] Xiao-jun Xu,et al. Nociceptin or antinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat. , 1996, Neuroreport.
[264] D. Grandy,et al. Orphanin FQ acts as a supraspinal, but not a spinal, anti‐opioid peptide , 1996, Neuroreport.
[265] K. Chang,et al. The stimulatory effect of opioids on mitogen-activated protein kinase in Chinese hamster ovary cells transfected to express mu-opioid receptors. , 1996, Molecular pharmacology.
[266] B. Chieng,et al. The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons. , 1996, Molecular pharmacology.
[267] V. Pickel,et al. Ultrastructural localization of μ-opioid receptors in the superficial layers of the rat cervical spinal cord: extrasynaptic localization and proximity to Leu5-enkephalin , 1996, Brain Research.
[268] V. Pickel,et al. Ultrastructural Evidence for Prominent Distribution of the μ-Opioid Receptor at Extrasynaptic Sites on Noradrenergic Dendrites in the Rat Nucleus Locus Coeruleus , 1996, The Journal of Neuroscience.
[269] M. Parmentier,et al. Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[270] K. Shark,et al. kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[271] E. Kempner,et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[272] V. Pickel,et al. Ultrastructural Immunocytochemical Localization of μ-Opioid Receptors in Rat Nucleus Accumbens: Extrasynaptic Plasmalemmal Distribution and Association with Leu5-Enkephalin , 1996, The Journal of Neuroscience.
[273] B. Tabakoff,et al. mu-Opioid receptors inhibit dopamine-stimulated activity of type V adenylyl cyclase but enhance dopamine-stimulated activity of type VII adenylyl cyclase. , 1996, Molecular pharmacology.
[274] A. Zimprich,et al. Promoter Region and Alternatively Spliced Exons of the Rat μ‐Opioid Receptor Gene , 1996, Journal of neurochemistry.
[275] M. Connor,et al. The effect of nociceptin on Ca2+ channel current and intracellular Ca2+ in the SH‐SY5Y human neuroblastoma cell line , 1996, British journal of pharmacology.
[276] L. Toll,et al. Determination of activity for nociceptin in the mouse vas deferens. , 1996, European journal of pharmacology.
[277] T. Vanderah,et al. Opioid receptor types and subtypes: the delta receptor as a model. , 1996, Annual review of pharmacology and toxicology.
[278] T. Soong,et al. Determinants of the G protein-dependent opioid modulation of neuronal calcium channels. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[279] S. Husbands,et al. Morphinan cyclic imines and pyrrolidines containing a constrained phenyl group: High affinity opioid agonists , 1995 .
[280] Brigitte L. Kieffer,et al. Recent advances in molecular recognition and signal transduction of active peptides: Receptors for opioid peptides , 1995, Cellular and Molecular Neurobiology.
[281] Y. Wong,et al. Activation of Type II Adenylyl Cyclase by the Cloned μ‐Opioid Receptor: Coupling to Multiple G Proteins , 1995, Journal of neurochemistry.
[282] H. Kung,et al. Mu opioid receptor gene expression in immune cells. , 1995, Biochemical and biophysical research communications.
[283] D. Grandy,et al. Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor , 1995, Science.
[284] T. Kaneko,et al. Presynaptic localization of μ-opioid receptor-like immunoreactivity in retinal axon terminals within the terminal nuclei of the accessory optic tract: a light and electron microscope study in the rat , 1995, Neuroscience Letters.
[285] M. Dapoigny,et al. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome , 1995, Digestive Diseases and Sciences.
[286] T. Kaneko,et al. Co-localization of μ-opioid receptor-like and substance P-like immunoreactivities in axon terminals within the superficial layers of the medullary and spinal dorsal horns of the rat , 1995, Neuroscience Letters.
[287] D. Selley,et al. In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[288] B. Bloch,et al. kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[289] A. I. Brooks,et al. Cloning and functional characterization through antisense mapping of a kappa 3-related opioid receptor. , 1995, Molecular pharmacology.
[290] S. D. Glick,et al. Kappa opioid inhibition of morphine and cocaine self-administration in rats , 1995, Brain Research.
[291] H. Loh,et al. The kappa-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[292] H. Loh,et al. Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[293] H. Loh,et al. Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells. , 1995, Molecular Pharmacology.
[294] Z. Vogel,et al. κ‐Opioid receptor‐transfected cell lines: modulation of adenylyl cyclase activity following acute and chronic opioid treatments , 1995, FEBS letters.
[295] D. Grandy,et al. Kappa-opioid receptors couple to inwardly rectifying potassium channels when coexpressed by Xenopus oocytes. , 1995, Molecular pharmacology.
[296] Stanley J. Watson,et al. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications , 1995, Trends in Neurosciences.
[297] T. Kaneko,et al. Immunocytochemical localization of μ-opioid receptor in the rat caudate-putamen , 1995, Neuroscience Letters.
[298] C. Lupica. Delta and mu enkephalins inhibit spontaneous GABA-mediated IPSCs via a cyclic AMP-independent mechanism in the rat hippocampus , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[299] B. O'dowd,et al. Distinct distributions of mu, delta and kappa opioid receptor mRNA in rat brain. , 1994, Biochemical and biophysical research communications.
[300] M. Nishi,et al. Structure and chromosomal mapping of genes for the mouse kappa-opioid receptor and an opioid receptor homologue (MOR-C). , 1994, Biochemical and biophysical research communications.
[301] M. Dichter,et al. The cloned kappa opioid receptor couples to an N-type calcium current in undifferentiated PC-12 cells , 1994, Neuroscience.
[302] H. Rhim,et al. Opioid receptors modulate diverse types of calcium channels in the nucleus tractus solitarius of the rat , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[303] H. Matthes,et al. The human delta-opioid receptor: genomic organization, cDNA cloning, functional expression, and distribution in human brain. , 1994, Molecular pharmacology.
[304] R. Macdonald,et al. Mu- and kappa-opioid receptors selectively reduce the same transient components of high-threshold calcium current in rat dorsal root ganglion sensory neurons , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[305] H. Loh,et al. Genomic structure analysis of promoter sequence of a mouse mu opioid receptor gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[306] J. Flippen-Anderson,et al. Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist. , 1994, Journal of medicinal chemistry.
[307] B. Ozenberger,et al. cDNA Cloning of an orphan opiate receptor gene family member and its splice variant , 1994, FEBS letters.
[308] A. Ohnishi,et al. Aquaretic effect of the stable dynorphin-A analog E2078 in the human. , 1994, The Journal of pharmacology and experimental therapeutics.
[309] M. Chesselet,et al. Expression of Mu opioid receptor mRNA in rat brain: An in situ hybridization study at the single cell level , 1994, The Journal of comparative neurology.
[310] P. Rubin,et al. The cardiovascular and central nervous system effects in the human of U-62066E , 1994, European Journal of Clinical Pharmacology.
[311] R. Gottschlich,et al. EMD 61 753 as a favourable representative of structurally novel arylacetamido-type K opiate receptor agonists , 1994 .
[312] L. Urbán,et al. Opioids suppress spontaneous activity of polymodal nociceptors in rat paw skin induced by ultraviolet irradiation , 1994, Neuroscience.
[313] G. Bell,et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. , 1994, Molecular pharmacology.
[314] G. Uhl,et al. Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. , 1994, FEBS letters.
[315] J. Williams,et al. kappa-Opioid receptors also increase potassium conductance. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[316] A Goldstein,et al. Cloning and pharmacological characterization of a rat kappa opioid receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[317] Stanley J. Watson,et al. Cloning and pharmacological characterization of a rat μ opioid receptor , 1993, Neuron.
[318] Robert C. Thompson,et al. Delta opioid receptor mRNA distribution in the brain: Comparison to delta receptor binding and proenkephalin mRNA , 1993, Journal of Chemical Neuroanatomy.
[319] C. Chen,et al. Molecular cloning and expression of a rat kappa opioid receptor. , 1993, The Biochemical journal.
[320] Y. Chen,et al. Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. , 1993, The Biochemical journal.
[321] G. Uhl,et al. mu opiate receptor: cDNA cloning and expression. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[322] J. L. Howard,et al. A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86. , 1993, The Journal of pharmacology and experimental therapeutics.
[323] P. Schiller,et al. TIPP[psi]: a highly potent and stable pseudopeptide delta opioid receptor antagonist with extraordinary delta selectivity. , 1993, Journal of medicinal chemistry.
[324] K. Mori,et al. cDNA cloning and pharmacological characterization of an opioid receptor with high affinities for κ‐subtype‐selective ligands , 1993, FEBS letters.
[325] J. Bidlack,et al. The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line is coupled to adenylyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein. , 1993, The Journal of pharmacology and experimental therapeutics.
[326] F. Porreca,et al. Differential antagonism of bremazocine- and U69,593-induced antinociception by quadazocine: further functional evidence of opioid kappa receptor multiplicity in the mouse. , 1993, The Journal of pharmacology and experimental therapeutics.
[327] G. Bell,et al. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[328] Lei Yu,et al. Molecular cloning and functional expression of a mu opioid receptor from rat brain , 1994, Regulatory Peptides.
[329] B. Carter,et al. Go mediates the coupling of the mu opioid receptor to adenylyl cyclase in cloned neural cells and brain. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[330] S. Childers,et al. Relationship between kappa 1 opioid receptor binding and inhibition of adenylyl cyclase in guinea pig brain membranes. , 1993, Biochemical pharmacology.
[331] R. Edwards,et al. Cloning of a delta opioid receptor by functional expression. , 1992, Science.
[332] T. Hughes,et al. Binding and pharmacological evidence for a special subtype of delta opioid receptor on human and invertebrate immune cells , 1992, Journal of Neuroimmunology.
[333] C. Xie,et al. Mu opioid receptor-mediated modulation of synaptic currents in dentate granule cells of rat hippocampus. , 1992, Journal of neurophysiology.
[334] D. Ann,et al. Specific reduction of delta-opioid receptor binding in transfected NG108-15 cells. , 1992, Journal of Biological Chemistry.
[335] P. Rubin,et al. Mechanism of diuretic action of spiradoline (U-62066E)--a kappa opioid receptor agonist in the human. , 1991, British journal of clinical pharmacology.
[336] F. Porreca,et al. Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice. , 1991, The Journal of pharmacology and experimental therapeutics.
[337] P. Portoghese,et al. Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. , 1991, The Journal of pharmacology and experimental therapeutics.
[338] D. Taub,et al. Immunomodulatory activity of mu- and kappa-selective opioid agonists. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[339] R. Spanagel,et al. The Effects of Opioid Peptides on Dopamine Release in the Nucleus Accumbens: An In Vivo Microdialysis Study , 1990, Journal of neurochemistry.
[340] W. Sadee,et al. Regulation of Cyclic AMP by the μ‐Opioid Receptor in Human Neuroblastoma SH‐SY5Y Cells , 1990, Journal of neurochemistry.
[341] D. Rees,et al. CI‐977, a novel and selective agonist for the κ‐opioid receptor , 1990, British journal of pharmacology.
[342] A Herz,et al. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[343] A. Goldstein,et al. Multiple opioid receptors: ligand selectivity profiles and binding site signatures. , 1989, Molecular pharmacology.
[344] D. Barra,et al. Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for delta opioid binding sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[345] N. Sharif,et al. Discrete mapping of brain mu and delta opioid receptors using selective peptides: Quantitative autoradiography, species differences and comparison with kappa receptors , 1989, Peptides.
[346] T. Shippenberg,et al. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. , 1989, The Journal of pharmacology and experimental therapeutics.
[347] K. Rice,et al. Selective and enantiospecific acylation of kappa opioid receptors by (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexy l] benzeneacetamide. Demonstration of kappa receptor heterogeneity. , 1989, Journal of medicinal chemistry.
[348] T. Blackburn,et al. Autoradiographic localization of delta opiate receptors in rat and human brain , 1988, Neuroscience.
[349] A. Cowan,et al. Role of Opioid Receptors in Bombesin‐induced Grooming a , 1988, Annals of the New York Academy of Sciences.
[350] B. Roques,et al. [3H][D-Ser2(O-tert-butyl),Leu5]enkephalyl-Thr6 and [D-Ser2(O-tert-butyl),Leu5]enkephalyl-Thr6(O-tert-butyl). Two new enkephalin analogs with both a good selectivity and a high affinity toward delta-opioid binding sites. , 1988, The Journal of biological chemistry.
[351] G. Di Chiara,et al. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. , 1988, The Journal of pharmacology and experimental therapeutics.
[352] D. L. Larson,et al. Hybrid bivalent ligands with opiate and enkephalin pharmacophores. , 1987, Journal of medicinal chemistry.
[353] H. Akil,et al. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain , 1987 .
[354] J T Williams,et al. Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[355] R. Zukin,et al. Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[356] K. Gulya,et al. Autoradiographic localization of [3H] [MePhe3,D-Pro4]morphiceptin ([3H]PL017) to mu opioid receptors in rat brain. , 1987, European journal of pharmacology.
[357] A. Pfeiffer,et al. Effects of a kappa-opioid agonist on adrenocorticotropic and diuretic function in man. , 1986, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[358] V. Hruby,et al. Cyclic somatostatin octapeptide analogues with high affinity and selectivity toward mu opioid receptors. , 1986, Life sciences.
[359] D. Zichi,et al. Factors affecting binding of trans-N-[2-(methylamino)cyclohexyl]benzamides at the primary morphine receptor. , 1985, Journal of medicinal chemistry.
[360] V. Hruby,et al. Characterization of [3H][2-D-penicillamine, 5-D-penicillamine]-enkephalin binding to delta opiate receptors in the rat brain and neuroblastoma--glioma hybrid cell line (NG 108-15). , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[361] H. Loh,et al. Multiple affinity states of opiate receptor in neuroblastoma x glioma NG108-15 hybrid cells. Opiate agonist association rate is a function of receptor occupancy. , 1985, The Journal of biological chemistry.
[362] J. Leander. Kappa Opioid Agonists and Antagonists: Effects on Drinking and Urinary Output , 1984, Appetite.
[363] J. K. Chang,et al. Potent morphiceptin analogs: structure activity relationships and morphine-like activities. , 1983, The Journal of pharmacology and experimental therapeutics.
[364] T F Burks,et al. Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[365] A. Korczyn,et al. The pupillary effects of opioids. , 1983, Life sciences.
[366] A. Tavani,et al. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties , 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.
[367] J. H. Ludens,et al. Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocyclazocine. , 1982, The Journal of pharmacology and experimental therapeutics.
[368] C. Chavkin,et al. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. , 1982, Science.
[369] M. Tyers. A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS , 1980, British journal of pharmacology.
[370] L. Hood,et al. Dynorphin-(1-13), an extraordinarily potent opioid peptide. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[371] M. Nirenberg,et al. Opiate-dependent modulation of adenylate cyclase. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[372] John Hughes,et al. Endogenous opioid peptides: multiple agonists and receptors , 1977, Nature.
[373] A. Goldstein,et al. Opioid activity of a peptide, beta-lipotropin-(61-91), derived from beta-lipotropin. , 1976, Proceedings of the National Academy of Sciences of the United States of America.
[374] J. Thompson,et al. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. , 1976, The Journal of pharmacology and experimental therapeutics.
[375] H. Morris,et al. Identification of two related pentapeptides from the brain with potent opiate agonist activity , 1975, Nature.
[376] F. Leslie,et al. EFFECT OF MORPHINE ON ADRENERGIC TRANSMISSION IN THE MOUSE VAS DEFERENS. ASSESSMENT OF AGONIST AND ANTAGONIST POTENCIES OF NARCOTIC ANALGESICS , 1975, British journal of pharmacology.
[377] E. J. Simon,et al. Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[378] S. Snyder,et al. Opiate Receptor: Demonstration in Nervous Tissue , 1973, Science.
[379] P. Portoghese. A new concept on the mode of interaction of narcotic analgesics with receptors. , 1965, Journal of medicinal chemistry.
[380] A H BECKETT,et al. SYNTHETIC ANALGESICS: STEREOCHEMICAL CONSIDERATIONS , 1954, The Journal of pharmacy and pharmacology.
[381] H. Kai,et al. Discovery of naldemedine: A potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects. , 2019, Bioorganic & medicinal chemistry letters.
[382] R. Stevens,et al. Structure of the human k-opioid receptor in complex with JDTic , 2012 .
[383] J. Bidlack,et al. Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. , 2009, Bioorganic & Medicinal Chemistry Letters.
[384] M. Bruchas,et al. Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. , 2007, The Journal of biological chemistry.
[385] J. Cassel,et al. Amino acid conjugates as kappa opioid receptor agonists. , 2005, Bioorganic & medicinal chemistry letters.
[386] David J. Daniels,et al. Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells. , 2005, Molecular pharmacology.
[387] Y. Wong,et al. Signal transducer and activator of transcription 3 activation by the delta-opioid receptor via Galpha14 involves multiple intermediates. , 2004, Molecular pharmacology.
[388] J. Felger,et al. Nociceptin/Orphanin FQ Increases Anxiety-Related Behavior and Circulating Levels of Corticosterone During Neophobic Tests of Anxiety , 2004, Neuropsychopharmacology.
[389] E. Butelman,et al. Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. , 2004, Psychopharmacology.
[390] Zhe Ding,et al. kappa Opioid receptor interacts with Na(+)/H(+)-exchanger regulatory factor-1/Ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) to stimulate Na(+)/H(+) exchange independent of G(i)/G(o) proteins. , 2004, The Journal of biological chemistry.
[391] David J. Daniels,et al. A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers. , 2004, Journal of medicinal chemistry.
[392] U. Holzgrabe,et al. Comparison of Pharmacological Activities of Three Distinct (cid:1) Ligands (Salvinorin A, TRK-820 and 3FLB) on (cid:1) Opioid Receptors in Vitro and Their Antipruritic and Antinociceptive Activities in Vivo , 2004 .
[393] A. Beaudet,et al. Regulation of delta-opioid receptor trafficking via mu-opioid receptor stimulation: evidence from mu-opioid receptor knock-out mice. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[394] J. R. Palacio,et al. The expression of delta- and kappa-opioid receptor is enhanced during intestinal inflammation in mice. , 2003, The Journal of pharmacology and experimental therapeutics.
[395] N. Mello,et al. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors. , 2003, Journal of medicinal chemistry.
[396] Angel Y. F. Kam,et al. Rac and Cdc42-dependent regulation of c-Jun N-terminal kinases by the delta-opioid receptor. , 2003, Journal of neurochemistry.
[397] Paul Ernsberger,et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[398] J. Kamei,et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. , 2002, European journal of pharmacology.
[399] D. Filliol,et al. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[400] P. Prather,et al. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors. , 2002, The Journal of pharmacology and experimental therapeutics.
[401] R. Dannals,et al. [(11)C]-GR89696, a potent kappa opiate receptor radioligand; in vivo binding of the R and S enantiomers. , 2002, Nuclear medicine and biology.
[402] H. Nagase,et al. Synthesis of optically active TAN-67, a highly selective delta opioid receptor agonist, and investigation of its pharmacological properties. , 2001, Drug design and discovery.
[403] J. Pintar,et al. Quantitative autoradiographic mapping of the ORL1, mu-, delta- and kappa-receptors in the brains of knockout mice lacking the ORL1 receptor gene. , 2001, Brain research.
[404] J. Pintar,et al. Expression of functional mu-opioid receptors during T cell development. , 2001, Journal of neuroimmunology.
[405] D. Filliol,et al. Autoradiographic mapping of the opioid receptor-like 1 (ORL1) receptor in the brains of mu-, delta- or kappa-opioid receptor knockout mice. , 2001, Neuroscience.
[406] P. Singhal,et al. Opiates promote T cell apoptosis through JNK and caspase pathway. , 2001, Advances in experimental medicine and biology.
[407] A. Coop,et al. BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice. , 2000, The Journal of pharmacology and experimental therapeutics.
[408] P. Clarke,et al. Antihyperalgesic effects of delta opioid agonists in a rat model of chronic inflammation. , 2000, British journal of pharmacology.
[409] R. M. Jones,et al. 5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. , 2000, European journal of pharmacology.
[410] A. McKnight,et al. Characterization of the ORL(1) receptor on adrenergic nerves in the rat anococcygeus muscle. , 2000, British journal of pharmacology.
[411] H. Loh,et al. Molecular mechanisms and regulation of opioid receptor signaling. , 2000, Annual review of pharmacology and toxicology.
[412] C. Mandyam,et al. beta-Funaltrexamine inactivates ORL1 receptors in BE(2)-C human neuroblastoma cells. , 2000, European journal of pharmacology.
[413] A. Dierich,et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. , 2000, Nature genetics.
[414] H. Akil,et al. Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists. , 1999, British journal of pharmacology.
[415] A. Ho,et al. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. , 1999, The Journal of pharmacology and experimental therapeutics.
[416] U. Scheffel,et al. Selective in vivo binding of [3H]naltriben to delta-opioid receptors in mouse brain. , 1998, European journal of pharmacology.
[417] Y. Wong,et al. Differential coupling of mu-, delta-, and kappa-opioid receptors to G alpha16-mediated stimulation of phospholipase C. , 1998, Journal of neurochemistry.
[418] V. Ganapathy,et al. Cloning and functional characterization of a sigma receptor from rat brain. , 1998, Journal of neurochemistry.
[419] A. Kastin,et al. A potent and selective endogenous agonist for the mu-opiate receptor. , 1997, Nature.
[420] R. Quock,et al. Relative efficacies of delta-opioid receptor agonists at the cloned human delta-opioid receptor. , 1997, European journal of pharmacology.
[421] H. Matthes,et al. Quantitative autoradiographic mapping of mu-, delta- and kappa-opioid receptors in knockout mice lacking the mu-opioid receptor gene. , 1997, Brain research.
[422] L. Liu-Chen,et al. Dual ultrastructural immunocytochemical labeling of mu and delta opioid receptors in the superficial layers of the rat cervical spinal cord. , 1997, Brain research.
[423] K. Fukuda,et al. Functional coupling of the delta-, mu-, and kappa-opioid receptors to mitogen-activated protein kinase and arachidonate release in Chinese hamster ovary cells. , 1996, Journal of neurochemistry.
[424] D. Grandy,et al. Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. , 1996, Neuroscience letters.
[425] S. Childers,et al. Identification of opioid receptor-like (ORL1) peptide-stimulated [35S]GTP gamma S binding in rat brain. , 1996, Neuroreport.
[426] E. J. Simon,et al. Autoradiographic comparison of [3H]DPDPE and [3H]DSLET binding: evidence for distinct delta 1 and delta 2 opioid receptor populations in rat brain. , 1996, Brain research.
[427] V. Pickel,et al. mu Opiate receptor immunoreactivity in rat central nervous system. , 1996, Neurochemical research.
[428] K. Mackie,et al. Modulation of Ca2+ channels by G-protein beta gamma subunits. , 1996, Nature.
[429] H. Loh,et al. Cloning and promoter mapping of mouse kappa opioid receptor gene. , 1995, Biochemical and biophysical research communications.
[430] F. Simonin,et al. Identification of kappa- and delta-opioid receptor transcripts in immune cells. , 1995, FEBS letters.
[431] Y. Wong,et al. Gz coupling to the rat kappa-opioid receptor. , 1995, FEBS letters.
[432] C. Chen,et al. Cloning of a human kappa opioid receptor from the brain. , 1995, Life sciences.
[433] T. Eisenstein,et al. Sequence of kappa-opioid receptor cDNA in the R1.1 thymoma cell line. , 1995, Journal of neuroimmunology.
[434] H. Ueda,et al. Opioid mu- and kappa-receptor mediate phospholipase C activation through Gi1 in Xenopus oocytes. , 1995, Brain research. Molecular brain research.
[435] K. Fukuda,et al. Coupling of the cloned mu-opioid receptor with the omega-conotoxin-sensitive Ca2+ current in NG108-15 cells. , 1995, Journal of neurochemistry.
[436] M. Mortrud,et al. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. , 1994, FEBS letters.
[437] D. Yang,et al. Isolation of a human kappa opioid receptor cDNA from placenta. , 1994, Biochemical and biophysical research communications.
[438] B. O'dowd,et al. Cloning, characterization, and distribution of a mu-opioid receptor in rat brain. , 1994, Journal of neurochemistry.
[439] M. Satoh,et al. Molecular cloning and in situ hybridization histochemistry for rat mu-opioid receptor. , 1994, Neuroscience research.
[440] R J Knapp,et al. Identification of a human delta opioid receptor: cloning and expression. , 1994, Life sciences.
[441] C. Kozak,et al. Murine chromosomal location of the mu and kappa opioid receptor genes. , 1994, Genomics.
[442] S. Kaneko,et al. Cloning and expression of a cDNA for the rat kappa-opioid receptor. , 1993, FEBS letters.
[443] K. Mori,et al. Primary structures and expression from cDNAs of rat opioid receptor delta- and mu-subtypes. , 1993, FEBS letters.
[444] F. Porreca,et al. Lack of cross-tolerance between U69,593 and bremazocine suggests kappa-opioid receptor multiplicity in mice. , 1993, European journal of pharmacology.
[445] G H Loew,et al. Molecular determinants of mu receptor recognition for the fentanyl class of compounds. , 1992, Molecular pharmacology.
[446] M. Adler,et al. Effect of mu-, kappa-, and delta-selective opioid agonists on thermoregulation in the rat. , 1992, Pharmacology, biochemistry, and behavior.
[447] A. Borsodi,et al. Synthesis and binding characteristics of the highly delta-specific new tritiated opioid peptide, [3H]deltorphin II. , 1992, Life sciences.
[448] T. Nakazawa,et al. Spinal kappa receptor-mediated analgesia of E-2078, a systemically active dynorphin analog, in mice. , 1991, The Journal of pharmacology and experimental therapeutics.
[449] I. Zagon,et al. Zeta (zeta), a growth-related opioid receptor in developing rat cerebellum: identification and characterization. , 1991, Brain research.
[450] D. Besse,et al. Autoradiographic distribution of mu, delta and kappa opioid binding sites in the superficial dorsal horn, over the rostrocaudal axis of the rat spinal cord. , 1991, Brain Research.
[451] R. Zukin,et al. Neuroanatomical localization of kappa 1 and kappa 2 opioid receptors in rat and guinea pig brain. , 1991, Brain research.
[452] H. Yoshino,et al. Synthesis and structure-activity relationships of dynorphin A-(1-8) amide analogues. , 1990, Journal of medicinal chemistry.
[453] J. Besson,et al. Pre- and postsynaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. , 1990, Brain research.
[454] K. Rice,et al. Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypes. , 1989, European journal of pharmacology.
[455] C. Smith,et al. Opioid receptors in the mouse ileum. , 1988, Archives internationales de pharmacodynamie et de therapie.
[456] K. Rice,et al. Mu-, delta- and kappa-opioid receptor-mediated inhibition of neurotransmitter release and adenylate cyclase activity in rat brain slices: studies with fentanyl isothiocyanate. , 1988, European journal of pharmacology.
[457] T. Cicero,et al. Autoradiography of [3H]U-69593 binding sites in rat brain: evidence for kappa opioid receptor subtypes. , 1988, European journal of pharmacology.
[458] P. Portoghese,et al. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. , 1988, European journal of pharmacology.
[459] M. Yeadon,et al. Comparative binding of mu and delta selective ligands in whole brain and pons/medulla homogenates from rat: affinity profiles of fentanyl derivatives. , 1988, Neuropharmacology.
[460] V. Hruby,et al. Quantitative autoradiography of [3H]CTOP binding to mu opioid receptors in rat brain. , 1988, Life sciences.
[461] M. Adler,et al. Hypothermia and poikilothermia induced by a kappa-agonist opioid and a neuroleptic. , 1987, European journal of pharmacology.
[462] T. Shippenberg,et al. Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists. , 1987, Brain research.
[463] B. Attali,et al. Inhibition of adenylate cyclase and induction of heterologous desensitization by kappa agonists in rat spinal cord. , 1986, NIDA research monograph.
[464] L. Krulich,et al. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. II. GH and PRL release-inhibiting effects of the opioid kappa receptor agonists bremazocine and U-50,488. , 1986, Neuroendocrinology.
[465] K. Mann,et al. Anterior pituitary hormone responses to a kappa-opioid agonist in man. , 1986, The Journal of clinical endocrinology and metabolism.
[466] V. Hruby,et al. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. , 1986, Journal of medicinal chemistry.
[467] J. Morley,et al. The kappa opioid receptor and food intake. , 1985, European journal of pharmacology.
[468] J. Mccall,et al. [3H]U-69593 a highly selective ligand for the opioid kappa receptor. , 1985, European journal of pharmacology.
[469] W. Sadee,et al. Characterization of a labile naloxone binding site (lambda site) in rat brain. , 1985, Journal of neurochemistry.
[470] T. Yaksh,et al. The physiology and pharmacology of spinal opiates. , 1985, Annual review of pharmacology and toxicology.
[471] T. Yaksh,et al. In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differential association of mu, delta and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat. , 1984, The Journal of pharmacology and experimental therapeutics.
[472] C. Chavkin,et al. Comparison of dynorphin-selective Kappa receptors in mouse vas deferens and guinea pig ileum. Spare receptor fraction as a determinant of potency. , 1983, Molecular pharmacology.
[473] R. Lahti,et al. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. , 1983, The Journal of pharmacology and experimental therapeutics.
[474] B. Morgan,et al. Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors. , 1981, European journal of pharmacology.
[475] R. Schulz,et al. Specificity of opioids towards the mu-, delta- and epsilon-opiate receptors. , 1979, Neuroscience letters.